For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260408:nRSH5294Za&default-theme=true
RNS Number : 5294Z Craneware plc 08 April 2026
8 April 2026
Craneware plc
("Craneware" or the "Company" or the "Group")
Transaction in Own Shares
Craneware (AIM: CRW.L), a leader in healthcare financial performance
solutions, announces today it has purchased the following number of its
Ordinary Shares of 1 pence each through Investec Bank plc ("Investec") in the
period from 31 March 2026 to 2 April 2026.
The table below contains detailed information about the purchases made as part
of the buyback programme which was announced by the Company on 16 March 2026
(the "Programme").
Date Venue Volume-weighted average price (p) Aggregated volume Lowest price per share (p) Highest price per share (p)
31 March 2026 AIMX 1321.5132 13,666 1300.0000 1325.0000
31 March 2026 XLON 1315.8952 14,947 1295.0000 1345.0000
01 April 2026 AIMX 1333.4483 14,500 1315.0000 1360.0000
01 April 2026 XLON 1354.4483 15,000 1305.0000 1375.0000
02 April 2026 AIMX 1319.7553 4,883 1315.0000 1330.0000
02 April 2026 XLON 1329.6300 15,000 1300.0000 1345.0000
The Company intends to hold the purchased shares in Treasury.
Following the above transactions, the Company will hold 539,559 Ordinary
Shares in Treasury and has 35,002,610 Ordinary Shares in issue (excluding
Treasury shares).
The figure of 35,002,610 represents the total voting rights in the Company and
may be used by shareholders as the denominator for calculating whether they
are required to notify their interest in, or a change to their interest in,
the Company under the FCA's Disclosure Guidance and Transparency Rules.
Individual Transactions
In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No
596/2014 as it forms part of UK law, a full breakdown of the individual trades
made by the Investec on behalf of the Company as part of the buyback programme
is attached to this announcement.
http://www.rns-pdf.londonstockexchange.com/rns/5294Z_1-2026-4-7.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/5294Z_1-2026-4-7.pdf)
For further information please contact:
Craneware plc +44 (0)131 550 3100
Keith Neilson, CEO
Craig Preston, CFO
Alma Strategic Communications +44 (0)20 3405 0205
Caroline Forde, Kinvara Verdon, Louisa El-Ahwal craneware@almastrategic.com
About Craneware
For over 25 years, The Craneware Group (AIM:CRW.L) has been a leader in
healthcare financial and operational transformation, delivering cutting-edge
technologies that drive measurable impact. Our Trisus(®) cloud ecosystem
unifies data, revenue intelligence, margin intelligence, and advanced
analytics, enabling healthcare organizations to optimize performance, improve
financial sustainability, and drive strategic growth. As a trusted Microsoft
partner, we provide future-ready solutions-including the Best in KLAS Trisus
Chargemaster - that simplify the complexities of healthcare finance and
operations. What sets us apart is our unique combination of deep healthcare
expertise and engineering excellence, positioning us as a strategic partner
rather than just a technology provider. The Craneware Group empowers
healthcare organizations to achieve sustainable financial success while
delivering better outcomes for the communities they serve - today and in the
future. Together, we are transforming the business of healthcare.
Learn more at www.thecranewaregroup.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END POSUPUGWCUPQGQM
Copyright 2019 Regulatory News Service, all rights reserved